Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LORYNA vs ALTAVERA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective mineralocorticoid receptor antagonist, blocking aldosterone binding to the mineralocorticoid receptor in epithelial and nonepithelial tissues.
Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.
Chronic heart failure (NYHA class II–IV) with reduced ejection fraction,Hypertension
Prevention of pregnancy,Treatment of moderate acne vulgaris (in females ≥15 years with no contraindications)
5 mg orally once daily, with or without food. Maximum dose 10 mg once daily.
1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.
Terminal elimination half-life is 18–24 hours in healthy adults; may be prolonged in severe hepatic impairment.
Levonorgestrel: terminal elimination half-life 25±10 hours; ethinyl estradiol: 13±7 hours. Clinical context: steady-state concentrations achieved within 5-7 days; contraceptive efficacy requires consistent daily dosing.
Hepatic via CYP3A4
Ethinyl estradiol: primarily metabolized by CYP3A4; undergoes sulfation and glucuronidation. Desogestrel: rapidly converted to active metabolite etonogestrel via CYP2C9 and CYP2C19; further metabolism by CYP3A4.
Primarily excreted via feces (80%) after biliary elimination; renal excretion accounts for approximately 10% as unchanged drug and metabolites.
Renal excretion of metabolites and unchanged drug: ~30% (levonorgestrel) and ~20% (ethinyl estradiol) in urine; biliary/fecal elimination: ~40-50% as conjugates and metabolites.
High protein binding (>99%) mainly to albumin and alpha-1-acid glycoprotein.
Levonorgestrel: 98-99% bound to sex hormone-binding globulin (SHBG) and albumin; ethinyl estradiol: 98% bound to albumin.
Volume of distribution is 0.4–0.6 L/kg, indicating distribution into total body water and some tissue binding.
Levonorgestrel: Vd ~1.8 L/kg (suggesting extensive tissue distribution). Ethinyl estradiol: Vd ~2.4 L/kg.
Oral bioavailability is approximately 50–60% due to extensive first-pass metabolism.
Oral bioavailability: levonorgestrel ~100% (nearly complete); ethinyl estradiol ~45-50% (first-pass hepatic metabolism).
GFR 30-89 m L/min: No adjustment. GFR 15-29 m L/min: 2.5 mg once daily. GFR <15 m L/min or dialysis: Not recommended.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal disease or acute renal failure due to potential fluid retention.
Child-Pugh A: No adjustment. Child-Pugh B: 2.5 mg once daily. Child-Pugh C: Not recommended.
Contraindicated in severe hepatic dysfunction (Child-Pugh class B or C). Use caution in mild to moderate impairment (Child-Pugh A); monitor liver enzymes.
Not established for patients under 18 years.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults (1 tablet daily, 21/7 regimen) after evaluation of risks.
Start at 2.5 mg once daily due to increased sensitivity; titrate based on response and tolerability.
Not indicated for postmenopausal women. No specific geriatric dosing; consider increased risk of thromboembolism, cardiovascular disease, and metabolic effects in older women of reproductive age.
None
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age (especially >35 years) and with number of cigarettes smoked. Women who use combined hormonal contraceptives should be strongly advised not to smoke.
Hyperkalemia,Renal impairment,Additive effect with other potassium-sparing diuretics or ACE inhibitors/ARBs
Thrombotic disorders: risk of venous thromboembolism (VTE), stroke, myocardial infarction; discontinue if thrombotic event occurs.,Hepatic disease: discontinue if jaundice or liver function abnormalities develop.,Hypertension: monitor blood pressure; discontinue if uncontrolled.,Carbohydrate metabolism: may affect glucose tolerance; monitor diabetic patients.,Depression: discontinue if significant depression occurs.,Gallbladder disease: increased risk of cholelithiasis.
Serum potassium >5.5 m Eq/L at initiation,Moderate to severe renal impairment (Cr Cl <30 m L/min),Concomitant use with strong CYP3A4 inhibitors
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Estrogen-dependent neoplasia (known or suspected),Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma (known or suspected),Pregnancy (known or suspected),Hypersensitivity to any component
Avoid grapefruit and grapefruit juice. No other significant food interactions. Maintain consistent dietary potassium intake.
No significant food interactions. Alcohol does not affect efficacy but may increase risk of adverse effects such as nausea. Grapefruit juice has no known interaction. Avoid excessive alcohol consumption due to potential hepatotoxicity.
First trimester: Increased risk of neural tube defects (anencephaly, spina bifida) and cardiovascular anomalies based on human data from antiepileptic drugs similar to topiramate. Second/third trimester: Risk of fetal growth restriction, low birth weight, and possibly preterm delivery. Overall, topiramate is considered teratogenic (Pregnancy Category D).
ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular defects (relative risk 1.2-1.4) and no consistent increase in other major malformations. Second and third trimesters: No known teratogenic effects, but theoretical risks from estrogenic effects (e.g., feminization of male fetus). Postnatal: No increased risk of long-term developmental effects from pregnancy exposure.
Topiramate is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 0.66. Infant serum levels can reach 10-20% of maternal therapeutic levels. Caution advised due to potential adverse effects (e.g., drowsiness, diarrhea, poor feeding). Use only if benefit outweighs risk.
Combined oral contraceptives may reduce milk production and quality, especially in early lactation. Ethinyl estradiol transfers into breast milk at low levels (M/P ratio approximately 0.1-0.2), excluding clinical effects in term infants. Levonorgestrel transfer is minimal (M/P ratio ~0.2-0.4). Use is generally avoided in breastfeeding women, especially during the first 6 weeks postpartum. Progestin-only methods are preferred.
Topiramate clearance increases by 20-30% during pregnancy, especially in second and third trimesters. Dose adjustment (often increase) may be necessary to maintain therapeutic efficacy, guided by clinical response and serum levels. Postpartum, clearance returns to prepregnancy levels; dose reduction should be considered to avoid toxicity.
Contraindicated in pregnancy. No dose adjustment recommended because use is discontinued upon confirmed or suspected pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased hepatic clearance, altered binding proteins) are not relevant for this indication.
LORYNA (drospirenone/ethinyl estradiol) is an oral contraceptive. Monitor potassium levels in patients with renal or hepatic impairment or on NSAIDs. Do not use in patients with hyperkalemia. Use with caution in patients predisposed to hyperkalemia.
ALTAVERA is a combined oral contraceptive (COC) containing ethinylestradiol and levonorgestrel. It inhibits ovulation via suppression of gonadotropins. Counsel patients to take at the same time daily to maintain efficacy. Missed pill management: if missed within 12 hours, take immediately; if >12 hours, take last missed pill and use backup contraception for 7 days. Be aware of increased VTE risk, especially in smokers over 35. May reduce effectiveness of lamotrigine; monitor seizure control. Initiate on the first day of menses or first Sunday after onset.
Take one tablet daily at the same time. Do not skip doses.,Use backup contraception if you miss a pill or have vomiting/diarrhea.,Avoid smoking, especially if over 35, due to increased cardiovascular risk.,Notify your doctor if you experience leg pain, shortness of breath, or severe headache.,This medication does not protect against HIV or other STDs.
Take one tablet daily at the same time each day, with or without food.,If you miss a pill by less than 12 hours, take it as soon as you remember. If more than 12 hours, take the missed pill and use a backup method (e.g., condoms) for the next 7 days.,Smoking increases your risk of serious cardiovascular side effects, especially if you are over 35 years old. Do not smoke while taking this medication.,Seek immediate medical attention if you experience sudden severe headache, chest pain, leg pain/swelling, or vision changes (symptoms of blood clots).,This medication does not protect against HIV or other sexually transmitted infections.,If you are taking lamotrigine or other anticonvulsants, tell your doctor; your seizure medication may be less effective.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LORYNA vs ALTAVERA, answered by our medical review team.
LORYNA is a Oral contraceptive that works by Selective mineralocorticoid receptor antagonist, blocking aldosterone binding to the mineralocorticoid receptor in epithelial and nonepithelial tissues.. ALTAVERA is a Combined Oral Contraceptive that works by Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LORYNA and ALTAVERA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LORYNA is: 5 mg orally once daily, with or without food. Maximum dose 10 mg once daily.. The standard adult dose of ALTAVERA is: 1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LORYNA and ALTAVERA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LORYNA is classified as Category C. First trimester: Increased risk of neural tube defects (anencephaly, spina bifida) and cardiovascular anomalies based on human data from antiepileptic drugs similar to topiramate. . ALTAVERA is classified as Category C. ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular def. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.